Rights issue in Cantargia AB (SE) — SEK 250 million

Carnegie acted as joint global co-ordinator in the fully guaranteed SEK 250 million rights issue in Cantargia. Cantargia is a biotechnology company that develops antibody-based treatments for life-threatening diseases and has established a platform based on the protein IL1RAP, involved in a number of cancer forms and inflammatory diseases. The main project, the antibody nadunolimab, is being studied clinically in combination with chemotherapy or immune therapy with a primary focus on non-small cell lung cancer and pancreatic cancer.
August 2022.